Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer

Burney, Basil O.; Hayes, Teresa G.; García, José Manuel Pérez

doi:10.1593/tlo.13346

Cited by 56 publications

(42 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antihypertensive agents include angiotensin‐converting enzyme inhibitors (ACEIs), angiotensin receptor antagonists/blockers (ARBs) and beta‐blockers (these will be reviewed later) and are typically prescribed to treat hypertension, congestive heart failure and diabetic nephropathy. ACEIs reduce the production of angiotensin II, whereas ARBs selectively inhibit the activation of the angiotensin II type 1 receptor . Angiotensin II plays an important role in the regulation of fluid and electrolyte balance and is also involved in cell growth, differentiation, apoptosis and angiogenesis .…”

Section: Antihypertensive Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Repurposing some older drugs that cross the blood–brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma

Rundle-Thiele

Head

Cosgrove

et al. 2015

Brit J Clinical Pharma

View full text Add to dashboard Cite

Glioblastoma is a brain neoplasm with limited 5‐year survival rates. Developments of new treatment regimens that improve patient survival in patients with glioblastoma are needed. It is likely that a number of existing drugs used in other conditions have potential anticancer effects that offer significant survival benefit to glioblastoma patients. Identification of such drugs could provide a novel treatment paradigm.

show abstract

Section: Antihypertensive Drugsmentioning

confidence: 99%

“…A number of retrospective analyses have investigated the impact of antihypertensive treatment on patient outcome in several cancers . Cardwell et al reported on the use of ACEIs and/or ARBs after diagnosis with either breast, colorectal or prostate cancer in over 20 000 patients in the UK .…”

Section: Antihypertensive Drugsmentioning

confidence: 99%

Repurposing some older drugs that cross the blood–brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma

Rundle-Thiele

Head

Cosgrove

et al. 2015

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Three articles were excluded as no usable data were reported (Wilop et al, 2009;Sendur et al, 2012;Moser et al, 2014). Three studies were also excluded as their reported data were not restricted to prediagnosis or postdiagnosis (Ganz et al, 2011;Engineer et al, 2013;Grytli et al, 2013). We further excluded four studies (Fletcher et al, 1993;Shah et al, 2011;Springate et al, 2015;Wong et al, 2015) that compared the effect of β blockers with that of other antihypertensive medications.…”

Section: Resultsmentioning

confidence: 99%

“…A number of epidemiologic studies have attempted to link the use of β blockers to mortality in patients with several cancer types including melanoma (Lemeshow et al, 2011;Livingstone et al, 2013;De Giorgi et al, 2014;McCourt et al, 2014;Moser et al, 2014), breast (Powe et al, 2010;Barron et al, 2011;Ganz et al, 2011;Melhem-Bertrandt et al, 2011;Sendur et al, 2012;Botteri et al, 2013;Cardwell et al, 2013;Holmes et al, 2013aHolmes et al, , 2013bSakellakis et al, 2015), colorectal (Engineer et al, 2013;Hicks et al, 2013;Holmes et al, 2013b;Jansen et al, 2014), prostate (Grytli et al, 2013(Grytli et al, , 2014Holmes et al, 2013b;Assayag et al, 2014;Cardwell et al, 2014), ovarian (Diaz et al, 2012;Johannesdottir et al, 2013), and lung cancer (Wilop et al, 2009;Aydiner et al, 2013;Wang et al, 2013;Holmes et al, 2013b;Cata et al, 2014); some have indicated that β-blocker use was associated with longer survival, whereas others showed no effect or a harmful effect. To date, no meta-analysis has investigated the impact of β-blocker use on the survival of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

β-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies

Zhong

Yu²,

Zhang³

et al. 2016

European Journal of Cancer Prevention

View full text Add to dashboard Cite

A number of epidemiologic studies have attempted to link the use of β blockers to mortality in cancer patients, but their findings have been inconclusive. A meta-analysis was carried out to derive a more precise estimation. Relevant studies were identified by searching PubMed and EMBASE to May 2015. We calculated the summary hazard ratios (HRs) and 95% confidence intervals (CIs) using random-effects models. Twenty cohort studies and four case-control studies involving 76 538 participants were included. The overall results showed that patients who used β blockers after diagnosis had an HR of 0.89 (95% CI 0.81-0.98) for all-cause mortality compared with nonusers. Those who used β blockers after diagnosis (vs. nonusers) had an HR of 0.89 (95% CI 0.79-0.99) for cancer-specific mortality. Prediagnostic use of β blockers showed no beneficial effect on all-cause mortality or cancer-specific mortality. Stratifying by cancer type, only breast cancer patients who used β blockers after diagnosis had a prolonged overall survival. A linear but nonsignificant trend was found between postdiagnostic β-blocker use and mortality of cancer patients. In conclusion, the average effect of β-blocker use after diagnosis but not before diagnosis is beneficial for the survival of cancer patients.

show abstract

“…Az ACE-gátló/ARB kezelés hatását vizsgál-va a colorectalis daganatok kockázata szempontjából [52] kiderült, hogy a tartós, nagy dózisú kezelések a colorectalis daganatok incidenciájának csökkenését eredményezhetik. A két RAS-gátló kombinált alkalmazásának kedvező hatása kimutatható volt mind a mortalitásra, mind pedig a túlélésre [53]. Más vizsgálatban nem talál-tak evidenciát arra vonatkozóan, hogy az ARB-vagy ACE-gátló kezelés fokozná a daganatspecifi kus mortalitást emlő-, colorectalis vagy prosztatatumor esetén [54].…”

Section: Klinikai Adatokunclassified

Oncology-related issues of angiotensin-receptor blockers

Telekes

Kiss

2015

Orvosi Hetilap

View full text Add to dashboard Cite

Az utóbbi időben ellentmondó adatok jelentek meg az angiotenzinreceptor-blokkolók daganatképződést fokozó hatásairól. A szakirodalomban az ellentmondásoknak számos oka lehet, többek között: rosszul tervezett vizsgálat, illetve hibás interpretáció. Tekintettel a kezelt hypertoniás betegek nagy számára, különösen fontos, hogy a magas vérnyomás kezelésére használt gyógyszerek onkológiai biztonságosságának kérdésében tisztán lássunk. Jelen közle-mény a rendelkezésre álló adatok áttekintésével igyekszik választ adni a felmerült kérdésekre. Az angiotenzinreceptorblokkolók daganatellenes hatásának, mai tudásunk szerint, nagyobb az esélye, mint a karcinogenezist fokozó hatás-nak. Erre mutatnak azok az onkológiai vizsgálatok, amelyekben az angiotenzinreceptor-blokkoló terápiát kiegészítő kezelésnek javasolják a kemoterápia mellé hasnyálmirigy-, nyelőcső-és gyomordaganatok esetén. Orv. Hetil., 2015, 156(11), 423-430. Kulcsszavak: angiotenzinreceptor-blokkolók, rákkeltő hatás, tumorellenes hatás Oncology-related issues of angiotensin-receptor blockersRecently controversial data emerged regarding the cancer inducing activity of angiotensin-receptor blockers. There may be several reasons which may explain the controversial data published in the scientifi c literature including wrong trial design or misinterpretation of data. Considering the large number of patients receiving treatment for hypertension, it is essential to have a clear view of the cancer-related safety of these drugs. This paper tries to give an overview on this issue based on data available in the literature. According to our present knowledge, angiotensin-receptor blockers exert more likely anticancer activity rather than carcinogenesis inducing effect. In fact, some oncologic trials point to this direction, because angiotensin-receptor blockers are suggested as co-treatment to chemotherapy in cases of pancreatic, oesophageal and gastric cancers. Keywords: angiotensin-receptor blockers, carcinogenesis, anticancer activityTelekes, A., Kiss, I. [Oncology-related issues of angiotensin-receptor blockers]. Orv. Hetil., 2015, 156(11), 423-430. (Beérkezett: 2015. január 14.; elfogadva: 2015. február 5.) Rövidítések ACE = angiotenzinkonvertáló enzim; ARB = angiotenzinreceptor-blokkoló; AT1R = angiotenzin-II-receptor-1; AT2R = angiotenzin-II-receptor-2; NO = nitrogén-monoxid; PSA = prosztataspecifi kus antigén; RAAS = renin-angiotenzin-aldoszteron rendszer; SIR = standardizált incidenciaarány; VEGF = vascularis endothelialis növekedési faktor A 2008. évi becslések szerint az összes halálozás hozzá-vetőleg 13,5%-a a hypertoniával hozható összefüggésbe [1], a daganatok vonatkozásában ugyanez az arány 13% volt (7,6 millió halálozás) [2]. Azóta, globálisan nézve, a daganatok okozta halálozás tovább növekedett. A 2012-es adatok szerint a daganatok okozta halálozás már 8,2 millió (14%) az összes halálozáshoz viszonyítva [3]. 2008-ban az új daganatos megbetegedések száma 12,7 millió volt, ez 2012-ben 14,1 millióra emelkedett. Ugyanezen idő alatt a hypertoniával összefüg...

show abstract

Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer

Cited by 56 publications

References 31 publications

Repurposing some older drugs that cross the blood–brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma

Repurposing some older drugs that cross the blood–brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma

β-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies

Oncology-related issues of angiotensin-receptor blockers

Contact Info

Product

Resources

About